← FDA DRUG APPROVALS

FDA NDA · NDA017508

LIDOCAINE HYDROCHLORIDE

Sponsor: ABRAXIS PHARM

APPLICATION
NDA017508
TYPE
NDA
ORIGINAL APPROVAL
1976-10-27
LATEST ACTION
1987-12-07
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

LIDOCAINE HYDROCHLORIDEDiscontinued
LIDOCAINE HYDROCHLORIDE 2% · INJECTABLE · INJECTION
LIDOCAINE HYDROCHLORIDEDiscontinued
LIDOCAINE HYDROCHLORIDE 20% · INJECTABLE · INJECTION
LIDOCAINE HYDROCHLORIDEDiscontinued
LIDOCAINE HYDROCHLORIDE 4% · INJECTABLE · INJECTION

Approval history

1987-12-07Labeling · Supplement 19AP
1982-12-13Labeling · Supplement 8AP
1981-03-02Labeling · Supplement 10AP
1980-01-08Labeling · Supplement 5AP
1979-07-10Labeling · Supplement 3AP
1978-11-01Labeling · Supplement 1AP
1976-10-27Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →